# Nalmefene Smoking Cessation Study

> **NCT00202696** · PHASE2 · COMPLETED · sponsor: **Somaxon Pharmaceuticals** · enrollment: 76 (actual)

## Conditions studied

- Smoking Cessation

## Interventions

- **DRUG:** nalmefene
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT00202696
- **Lead sponsor:** Somaxon Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-09
- **Primary completion:** 2006-03
- **Final completion:** 2006-03
- **Target enrollment:** 76 (ACTUAL)
- **Last updated:** 2008-05-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00202696

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00202696, "Nalmefene Smoking Cessation Study". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00202696. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*